Jeffrey Epstein arranged for his genetic material to survive him, according to documents released by the Justice Department. The disgraced financier deposited sperm with California Cryobank before 2012 and signed a contract in 2016 specifying that the samples should transfer to his estate upon his death.

CooperCompanies, which acquired California Cryobank in 2021, confirmed they no longer store Epstein's samples but declined to provide details about their disposal. The arrangement remained unknown until the recent file release, adding complexity to an estate already valued in the millions of dollars. Epstein left assets to Karyna Shuliak and roughly 40 other potential beneficiaries through a trust administered in the U.S. Virgin Islands.

Legal experts say the case highlights tensions in reproductive technology ethics. Professor Kimberly Mutcherson notes the fertility industry debates whether providers should screen clients based on criminal history, arguing such gatekeeping could enable discrimination. However, she acknowledges this case presents unique circumstances given Epstein's sex offender status.

The disclosure comes as the fertility industry grapples with expanding consumer demand and ethical boundaries. Sperm banking represents a growing market segment worth billions annually, though cases involving posthumous reproduction from controversial figures present unprecedented legal and moral questions for service providers.